CD Diagnostics Inc., which is developing "biomarkers" to track diseases in people, including the Synovasure joint-infection test for bone doctors, says it has shut its Wynnewood, Pa. and Logan Township, N.J. facilities and opened a 20,000 sq ft R&D, manufacturing and office location at Brandywine Corporate Center 1, Claymont, Del., that will employ 170 by 2016.
Delaware gave CD $500,000 from its Strategic Performance Fund for the facility on condition it add the promised jobs, state economic development chief Alan Levin said in a statement. Dr. Carl Deirmengian, CD's chief medical officer, credited the grant with helping build the "advanced manufacturing facility" to develop "several new products."
"We are excited about our move to Delaware," said CD boss Richard Birkmeyer in a statement, citing the local workforce, "easy access for our corporate partners," and the "thriving local economic and scientific community." CD also owns clinical-testing facility Citrano Medical Laboratories, Towson, Md.